Epstein-Barr virus-associated posttransplantation lymphoproliferative disorder after high-dose immunosuppressive therapy and autologous CD34-selected hematopoietic stem cell transplantation for severe autoimmune diseases
Richard A. Nash(Colorado Blood Cancer Institute), Peter A. McSweeney(Mesoblast (United States)), George E. Georges(Northwestern University), Chien-Shing Chen(Loma Linda University), Maureen D. Mayes(The University of Texas Health Science Center), Keith M. Sullivan(Duke Medical Center), Roger Dansey(Memorial Sloan Kettering Cancer Center), C.F. LeMaistre(City Of Hope National Medical Center), James D. Bowen(Swedish Medical Center), Daniel E. Furst(University of California, Los Angeles), John F. DiPersio(Washington University in St. Louis), Steven Z. Pavletic(National Institutes of Health), Jan Storek(University of Washington), George H. Kraft(Patara Pharma (United States)), Julie Sunderhaus(City Of Hope National Medical Center), Kevin T. McDonagh(University of Michigan), Leona Holmberg
Cited by 94
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group Report
|Biology of Blood and Marrow Transplantation|2014|5.4k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis
|Arthritis & Rheumatology|2015|2.8k
Chronic graft-versus-host syndrome in man
|The American Journal of Medicine|1980|2.4k